SCHEMBL884735

SCHEMBL884735

O=C1CN(c2ncccc2CC(c2cccnc2)c2cccnc2)CCN1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 12/20 0.43
KCNH2 Q12809 4/20 0.43
MAPT P10636 2/20 0.43
PRKCH P24723 1/20 0.40
PRKCE Q02156 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
SLC6A3 Q01959 1/20 0.39
METAP2 P50579 1/20 0.38
PIM1 P11309 1/20 0.38
PRMT5 O14744 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL884635 0.81 KCNA5 (0.51) KCNA5KCNH2MAPTALDH1A1SLC6A2
SCHEMBL884666 0.80 KCNA5 (0.50) KCNA5KCNH2MAPTALDH1A1SLC6A2
SCHEMBL2063140 0.79 GRIN2D (0.52) KCNA5KCNH2MAPTPRMT5
SCHEMBL884433 0.78 KCNA5 (0.46) KCNA5KCNH2ALDH1A1KMT2ASLC6A2
SCHEMBL884252 0.78 KCNA5 (0.48) KCNA5KCNH2SLC6A2SLC6A4SLC6A3
SCHEMBL884734 0.78 KCNA5 (0.48) KCNA5KCNH2ALDH1A1SMN1; SMN2
SCHEMBL5035484 0.77 KCNA5 (0.43) KCNA5KCNH2SLC6A2SLC6A4SLC6A3
SCHEMBL884510 0.75 KCNA5 (0.48) KCNA5KCNH2SLC6A2SLC6A4SLC6A3
SCHEMBL884542 0.75 KCNA5 (0.45) KCNA5KCNH2SLC6A2SLC6A4SLC6A3
SCHEMBL2063860 0.75 KCNA5 (0.45) KCNA5KCNH2SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US claimed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP claimed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO claimed
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885KCNH2 3/4885MAPT 2696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.